We reported previously that the disruption of c-Myc through mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) inhibition blocks the expression of the transformed phenotype in the embryonal rhabdomyosarcoma (ERMS) cell line (RD), thereby inducing myogenic differentiation in vitro. In this article, we investigate whether MEK/ERK inhibition, by the MEK/ERK inhibitor U0126, affects c-Myc protein level and growth of RMS tumor in an in vivo xenograft model. U0126 significantly reduced RMS tumor growth in RD cell line-xenotransplanted mice. Immunobiochemical and immunohistochemical analysis showed (a) phospho-active ERK levels were reduced by U0126 therapy and unaltered in normal tissues, (b) phospho-Myc and c-Myc was reduced commensurate with phospho-ERK inhibition, and (c) reduction in Ki-67 and endothelial (CD31) marker expression. These results indicate that MEK/ERK inhibition affects growth and angiogenic signals in tumor. The RD-M1 cultured xenograft tumor-derived cell line and the ERMS cell line TE671 responded to U0126 by arresting growth, down-regulating c-Myc, and initiating myogenesis. All these results suggest a tight correlation of MEK/ERK inhibition with c-Myc down-regulation and arrest of tumor growth. Thus, MEK inhibitors may be investigated for a signal transduction-based targeting of the c-Myc as a therapeutic strategy in ERMS. Copyright © 2009 American Association for Cancer Research.

MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma / Marampon, Francesco; Bossi, Gianluca; Ciccarelli, Carmela; Di Rocco, Agnese; Sacchi, Ada; Pestell, Richard G.; Zani, Bianca M.. - In: MOLECULAR CANCER THERAPEUTICS. - ISSN 1535-7163. - 8:3(2009), pp. 543-551. [10.1158/1535-7163.MCT-08-0570]

MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma

Marampon, Francesco;Zani, Bianca M.
2009

Abstract

We reported previously that the disruption of c-Myc through mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) inhibition blocks the expression of the transformed phenotype in the embryonal rhabdomyosarcoma (ERMS) cell line (RD), thereby inducing myogenic differentiation in vitro. In this article, we investigate whether MEK/ERK inhibition, by the MEK/ERK inhibitor U0126, affects c-Myc protein level and growth of RMS tumor in an in vivo xenograft model. U0126 significantly reduced RMS tumor growth in RD cell line-xenotransplanted mice. Immunobiochemical and immunohistochemical analysis showed (a) phospho-active ERK levels were reduced by U0126 therapy and unaltered in normal tissues, (b) phospho-Myc and c-Myc was reduced commensurate with phospho-ERK inhibition, and (c) reduction in Ki-67 and endothelial (CD31) marker expression. These results indicate that MEK/ERK inhibition affects growth and angiogenic signals in tumor. The RD-M1 cultured xenograft tumor-derived cell line and the ERMS cell line TE671 responded to U0126 by arresting growth, down-regulating c-Myc, and initiating myogenesis. All these results suggest a tight correlation of MEK/ERK inhibition with c-Myc down-regulation and arrest of tumor growth. Thus, MEK inhibitors may be investigated for a signal transduction-based targeting of the c-Myc as a therapeutic strategy in ERMS. Copyright © 2009 American Association for Cancer Research.
2009
Animals; antineoplastic agents; butadienes; cell proliferation; enzyme inhibitors; extracellular signal-regulated MAP Kinases; female; gene expression regulation; neoplastic; humans; MAP Kinase Kinase Kinases; mice; mice nude; muscle neoplasms; nitriles; proto-oncogene proteins c-myc; rhabdomyosarcoma embryonal; tumor cells cultured; xenograft model; antitumor assays; oncology; cancer research
01 Pubblicazione su rivista::01a Articolo in rivista
MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma / Marampon, Francesco; Bossi, Gianluca; Ciccarelli, Carmela; Di Rocco, Agnese; Sacchi, Ada; Pestell, Richard G.; Zani, Bianca M.. - In: MOLECULAR CANCER THERAPEUTICS. - ISSN 1535-7163. - 8:3(2009), pp. 543-551. [10.1158/1535-7163.MCT-08-0570]
File allegati a questo prodotto
File Dimensione Formato  
Marampon_Rhabdomyosarcoma.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 571.17 kB
Formato Adobe PDF
571.17 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1259185
Citazioni
  • ???jsp.display-item.citation.pmc??? 45
  • Scopus 90
  • ???jsp.display-item.citation.isi??? 89
social impact